Correction: Comprehensive biomarker analysis of metabolomics in different syndromes in traditional Chinese medical for prediabetes mellitus Authors: Qin Lan, Xue Li, Jianhe Fang, Xinyu Yu, Zhanxuan E Wu, Caiyun Yang, Hui Jian, Fei Li Published: 2025 Correction: Chinese Medicine (2024) 19:114. 10.1186/s13020-024-00983-1 Following publication of the original article [1], the authors found some mistakes in Tables 3 and 4. This error is due to the wrong input of the raw data. The HDL-C raw data of No.10 patient in PDMPXSK group is 1.02, not 102, which was used to calculate the numerical value of HDL-C in Table 3. The HDL-C raw data of No.10 patient in PDMPXSK group is 1.02, not 102, which was used to calculate the numerical value of HDL-C in Table 3. The insulin raw data of No. 2 and 7 in PDMSRYP is 14.41 and 18.02, not 4.41 and 8.02, respectively, which was used to calculate the numerical value of FINS, HOMA-IR, HOME-IS, HOMA-β in Table 4. The insulin raw data of No. 2 and 7 in PDMSRYP is 14.41 and 18.02, not 4.41 and 8.02, respectively, which was used to calculate the numerical value of FINS, HOMA-IR, HOME-IS, HOMA-β in Table 4. The correct Tables 3 and 4 have been provided in this Correction. The incorrect Table 3 is: Table 3Comparison of the glycolipid-related indicators between the normal blood glucose and PreDM group among the PXSK patientsNDMPXSK n = 20 (Male: 9 Female: 11)PDMPXSK n = 20 (Male: 9 Female: 11)t/zpSBP (mmHg)112.10 ± 7.13122.30 ± 11.503.3710.002**DBP (mmHg)73.85 ± 6.0877.85 ± 10.071.5210.137n.s.FBG (mmol/L)5.40 ± 0.395.82 ± 0.661.4580.153n.s.2 h PG (mmol/L)5.57 ± 0.928.88 ± 1.269.4890.001***HbA1c (%)4.76 ± 0.375.46 ± 0.495.1000.001***FINS (μU/mL)8.04 ± 5.586.60 ± 3.920.9440.351n.s.UA (mmol/L)363.90 ± 88.36295.48 ± 104.472.2360.031*TG (mmol/L)1.33 ± 0.591.92 ± 1.481.6600.106n.s.TC (mmol/L)4.63 ± 0.844.71 ± 1.050.2660.792n.s.HDL-C (mmol/L)1.33 ± 0.286.31 ± 2.259.8230.001***LDL-C (mmol/L)2.78 ± 0.582.96 ± 0.840.7890.435n.s.HOMA-IR1.91 ± 1.271.72 ± 1.090.5080.615n.s.HOMA-IS0.68 ± 0.300.82 ± 0.491.0900.283n.s.HOMA-β (%)93.40 ± 78.8461.72 ± 42.871.5790.123n.s.SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, 2-h PG 2-h blood post-load blood glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin, UA uric acid, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, HOMA-IS homeostatic model assessment for insulin sensibility, HOMA-β homeostatic model assessment of β-cell function. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001. The Mann–Whitney U test was used to test for significant differences between the groups, data are n (%) or mean ± SD Comparison of the glycolipid-related indicators between the normal blood glucose and PreDM group among the PXSK patients SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, 2-h PG 2-h blood post-load blood glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin, UA uric acid, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, HOMA-IS homeostatic model assessment for insulin sensibility, HOMA-β homeostatic model assessment of β-cell function. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001. The Mann–Whitney U test was used to test for significant differences between the groups, data are n (%) or mean ± SD The correct Table 3 is: Table 3Comparison of the glycolipid-related indicators between the normal blood glucose and PreDM group among the PXSK patientsNDMPXSKPDMPXSKt/zpSBP (mmHg)112.10 ± 7.13122.30 ± 11.503.3710.002**DBP (mmHg)73.85 ± 6.0877.85 ± 10.071.5210.137n.s.FPG (mmol/L)5.40 ± 0.395.82 ± 0.661.4580.153n.s.2hPG (mmol/L)5.57 ± 0.928.88 ± 1.269.4890.001***HbA1c (%)4.76 ± 0.375.46 ± 0.495.1000.001***FINS (μU/mL)8.04 ± 5.586.60 ± 3.920.9440.351n.s.UA (mmol/L)363.90 ± 88.36295.48 ± 104.472.2360.031*TG (mmol/L)1.33 ± 0.591.92 ± 1.481.6600.106n.s.TC (mmol/L)4.63 ± 0.844.71 ± 1.050.2660.792n.s.HDL-C (mmol/L)1.33 ± 0.281.65 ± 0.372.4980.017*LDL-C (mmol/L)2.78 ± 0.582.96 ± 0.840.7890.435n.s.HOMA-IR1.91 ± 1.271.72 ± 1.090.5080.615n.s.HOMA-IS0.68 ± 0.300.82 ± 0.491.0900.283n.s.HOMA-β (%)93.40 ± 78.8461.72 ± 42.871.5790.123n.s.SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, 2-h PG 2-h blood post-load blood glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin, UA uric acid, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, HOMA-IS homeostatic model assessment for insulin sensibility, HOMA-β homeostatic model assessment of β-cell function. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001. The Mann–Whitney U test was used to test for significant differences between the groups, data are n (%) or mean ± SD Comparison of the glycolipid-related indicators between the normal blood glucose and PreDM group among the PXSK patients SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, 2-h PG 2-h blood post-load blood glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin, UA uric acid, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, HOMA-IS homeostatic model assessment for insulin sensibility, HOMA-β homeostatic model assessment of β-cell function. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001. The Mann–Whitney U test was used to test for significant differences between the groups, data are n (%) or mean ± SD The incorrect Table 4 is: Table 4Comparison of the glycolipid-related indicators between the normal blood glucose group and PreDM group among the SRYP patientsNDMSRYP n = 20 (Male: 9 Female: 11)PDMSRYP n = 20 (Male: 12 Female: 8)t/zpSBP (mmHg)114.00 ± 13.24120.20 ± 10.891.6170.114n.s.DBP (mmHg)75.90 ± 10.1878.40 ± 7.760.8730.388n.s.FBG (mmol/L)5.35 ± 0.336.04 ± 0.554.8110.001***2 h PG (mmol/L)5.69 ± 1.139.12 ± 1.219.2650.001***HbA1c (%)4.83 ± 0.295.28 ± 0.632.9020.006**FINS (μU/mL)6.38 ± 4.499.87 ± 6.132.0540.047*UA (mmol/L)333.90 ± 100.23353.57 ± 118.890.5660.575n.s.TG (mmol/L)1.99 ± 1.801.96 ± 0.870.0700.947n.s.TC (mmol/L)4.32 ± 0.714.96 ± 1.242.0030.052n.s.HDL-C (mmol/L)1.25 ± 0.391.28 ± 0.370.2500.804n.s.LDL-C (mmol/L)2.86 ± 0.693.23 ± 0.971.3900.173n.s.HOMA-IR1.55 ± 1.141.69 ± 1.770.2970.768n.s.HOMA-IS0.96 ± 0.560.57 ± 0.402.5340.016*HOMA-β (%)66.86 ± 40.6679.25 ± 50.680.8530.399n.s.SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, 2-h PG 2-h blood post-load blood glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin, UA uric acid, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, HOMA-IS homeostatic model assessment for insulin sensibility, HOMA-β homeostatic model assessment of β-cell function. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001. The Mann–Whitney U test was used to test for significant differences between the groups, data are n (%) or mean ± SD Comparison of the glycolipid-related indicators between the normal blood glucose group and PreDM group among the SRYP patients SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, 2-h PG 2-h blood post-load blood glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin, UA uric acid, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, HOMA-IS homeostatic model assessment for insulin sensibility, HOMA-β homeostatic model assessment of β-cell function. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001. The Mann–Whitney U test was used to test for significant differences between the groups, data are n (%) or mean ± SD The correct Table 4 is: Table 4Comparison of the glycolipid-related indicators between the normal blood glucose group and PreDM group among the SRYP patientsNDMSRYPPDMSRYPt/zpSBP (mmHg)114.00 ± 13.24120.20 ± 10.891.6170.114n.s.DBP (mmHg)75.90 ± 10.1878.40 ± 7.760.8730.388n.s.FPG (mmol/L)5.35 ± 0.336.04 ± 0.554.8110.001***2hPG (mmol/L)5.69 ± 1.139.12 ± 1.219.2650.001***HbA1c (%)4.83 ± 0.295.28 ± 0.632.9020.006**FINS (μU/mL)6.38 ± 4.4910.87 ± 6.272.6060.013*UA (mmol/L)333.90 ± 100.23353.57 ± 118.890.5660.575n.s.TG (mmol/L)1.99 ± 1.801.96 ± 0.870.0700.947n.s.TC (mmol/L)4.32 ± 0.714.96 ± 1.242.0030.052n.s.HDL-C (mmol/L)1.25 ± 0.391.28 ± 0.370.2500.804n.s.LDL-C (mmol/L)2.86 ± 0.693.23 ± 0.971.3900.173n.s.HOMA-IR1.55 ± 1.142.95 ± 1.790.9500.005**HOMA-IS0.96 ± 0.560.53 ± 0.402.7940.008**HOMA-β (%)66.86 ± 40.6686.88 ± 53.561.3310.191n.s.SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, 2-h PG 2-h blood post-load blood glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin, UA uric acid, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, HOMA-IS homeostatic model assessment for insulin sensibility, HOMA-β homeostatic model assessment of β-cell function. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001. The Mann–Whitney U test was used to test for significant differences between the groups, data are n (%) or mean ± SD Comparison of the glycolipid-related indicators between the normal blood glucose group and PreDM group among the SRYP patients SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, 2-h PG 2-h blood post-load blood glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin, UA uric acid, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, HOMA-IS homeostatic model assessment for insulin sensibility, HOMA-β homeostatic model assessment of β-cell function. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001. The Mann–Whitney U test was used to test for significant differences between the groups, data are n (%) or mean ± SD The original article [1] has been corrected. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. †Qin Lan and Xue Li are co-authors and contributed equally to this article. Contributor Information Hui Jian, Email: Jianhui126@126.com. Fei Li, Email: feili@wchscu.cn. Reference